SECOND AMENDMENT TO COMMERCIAL LEASECommercial Lease • August 7th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
Duffy Hartwell LLC, as successor in interest to Duffy Hartwell Limited Partnership, (“LESSOR”) and Synta Pharmaceuticals Corporation, as successor in interest to Shionogi BioResearch Corp., (“LESSEE”) (the LESSOR and the LESSEE are collectively referred to as the “Parties” in this Second Amendment) are landlord and tenant, respectively, under a certain Commercial Lease (“Initial Lease Agreement”) dated November 4, 1996, as amended by a First Amendment to Commercial Lease (“First Amendment”; together with the Initial Lease Agreement, the “Lease Agreement”) dated August 30 2006, for approximately 24,420 rentable square feet, more or less, in the building (“the “Building”) located at 45 Hartwell Avenue, Lexington, MA and hereby agree as follows:
Amendment No. 1 to Collaborative Development, Commercialization and License AgreementCollaborative Development, Commercialization and License Agreement • August 7th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
This amendment (the “Amendment”) dated June 27, 2008 is to the Collaborative Development, Commercialization and License Agreement dated October 8, 2007 between Synta Pharmaceuticals Corp., a Delaware corporation with offices at 45 Hartwell Ave., Lexington, Massachusetts 02421 (“Synta”), and SmithKline Beecham Corporation, a Pennsylvania corporation with offices at One Franklin Plaza, Philadelphia, Pennsylvania 19101 (“GSK”) (the “Agreement”).
